1 week Ago By ABMN Staff
Tandem Diabetes Care ( NASDAQ:TNDM – Get Free Report ) is anticipated to announce its Q1 2025 earnings results after the market closes on Wednesday, April 30th. Analysts expect the company to announce earnings of ($0.60) per share and revenue of $220.
19 million for the quarter. Tandem Diabetes Care Trading Up 2.2 % NASDAQ TNDM opened at $18.
06 on Monday. The firm has a market capitalization of $1.20 billion, a P/E ratio of -9.
36 and a beta of 1.52. The business has a fifty day simple moving average of $20.
17 and a 200 day simple moving average of $29.17. Tandem Diabetes Care has a 12 month low of $15.
75 and a 12 month high of $53.69. The company has a current ratio of 2.
90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29.
Wall Street Analyst Weigh In TNDM has been the subject of a number of analyst reports. Morgan Stanley lowered Tandem Diabetes Care from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $45.00 to $22.
00 in a research report on Wednesday, March 5th. Citigroup lowered Tandem Diabetes Care from a “buy” rating to a “neutral” rating and lowered their price target for the company from $35.00 to $24.
00 in a research report on Tuesday, March 4th. Robert W. Baird lowered their price target on Tandem Diabetes Care from $37.
00 to $33.00 and set a “neutral” rating for the company in a research report on Thursday, February 27th. Royal Bank of Canada lowered their price target on Tandem Diabetes Care from $65.
00 to $55.00 and set an “outperform” rating for the company in a research report on Thursday, February 27th. Finally, Mizuho assumed coverage on Tandem Diabetes Care in a research report on Thursday, April 10th.
They set a “neutral” rating and a $20.00 target price for the company. Eight investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock.
According to data from MarketBeat, Tandem Diabetes Care presently has an average rating of “Moderate Buy” and an average target price of $43.81. Insider Activity at Tandem Diabetes Care In other news, COO Jean-Claude Kyrillos bought 10,538 shares of the firm’s stock in a transaction that occurred on Friday, March 7th.
The shares were acquired at an average price of $18.12 per share, with a total value of $190,948.56.
Following the acquisition, the chief operating officer now owns 10,538 shares of the company’s stock, valued at approximately $190,948.56. The trade was a ∞ increase in their position.
The acquisition was disclosed in a legal filing with the SEC, which is available through this link . 1.90% of the stock is currently owned by corporate insiders.
About Tandem Diabetes Care ( Get Free Report ) Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. Featured Articles Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.
com's FREE daily email newsletter ..
